The Synergistic Effect of Hypoglycemic Index Diet on Refractory Schizophrenia
NCT04302636 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2021-11-15
Summary
This experiment was conducted to investigate the improvement of hypoglycemic index diet (LGIT) as a potential new intervention scheme for treatment-resistant schizophrenia, and to further explore the mechanism of efficacy.
Conditions
- Refractory Schizophrenia
Interventions
- DIETARY_SUPPLEMENT
-
Low glycemic index diet
The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
Sponsors & Collaborators
-
Shanghai Jiao Tong University School of Medicine
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-24
- Primary Completion
- 2022-03-31
- Completion
- 2022-05-31
Countries
- China
Study Locations
More Related Trials
-
Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients
NCT01300637 ·Status: UNKNOWN ·Phase: NA
-
Pharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)
NCT00201292 ·Status: UNKNOWN
-
Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients
NCT01206153 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
NCT06331286 ·Status: UNKNOWN ·Phase: NA
-
Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients
NCT03708549 ·Status: UNKNOWN ·Phase: PHASE4
-
Pfizer/IVGTT/Ziprasidone/Olanzapine
NCT00205725 ·Status: COMPLETED ·Phase: NA
-
Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder
NCT00395031 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
NCT05333003 ·Status: RECRUITING ·Phase: NA
-
Berberine Treat Metabolic Syndrome in Schizophrenia
NCT03251716 ·Status: COMPLETED ·Phase: NA
-
Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness
NCT02167620 ·Status: COMPLETED ·Phase: PHASE4
-
Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
NCT05663749 ·Status: COMPLETED ·Phase: PHASE4
-
Glucose and Lipid Metabolism on Antipsychotic Medication
NCT00515723 ·Status: COMPLETED ·Phase: NA
-
Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism
NCT03675750 ·Status: UNKNOWN
-
Metformin for Treatment of Antipsychotic-induced Dyslipidemia
NCT01778244 ·Status: COMPLETED ·Phase: PHASE4
-
Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?
NCT07109245 ·Status: RECRUITING ·Phase: PHASE4
-
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
NCT00552500 ·Status: COMPLETED ·Phase: NA
-
The Impact of the Mediterranean Diet on Anthropometric Indices, Lipid Profiles, Energy Metabolism Signaling Proteins and Inflammatory Cytokines in Psychiatric Patients With Metabolic Syndrome
NCT07164014 ·Status: COMPLETED ·Phase: NA
-
Metformin for Weight Loss in Schizophrenia
NCT01177709 ·Status: TERMINATED ·Phase: NA
-
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
NCT05463770 ·Status: COMPLETED ·Phase: PHASE1
-
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
NCT04892199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
NCT00816907 ·Status: COMPLETED ·Phase: PHASE4
-
Lifestyle Intervention for Diabetes and Weight Management in Psychosis
NCT01828931 ·Status: COMPLETED ·Phase: NA
-
Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment
NCT06326840 ·Status: COMPLETED ·Phase: NA
-
The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity
NCT01384279 ·Status: COMPLETED ·Phase: NA
-
Antipsychotics and Risk of Hyperglycemic Emergencies
NCT02582736 ·Status: COMPLETED